Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 5, 2024
Emerging Company Profile
Tubulis: Enhancing ADC stability via new conjugation methods
German biotech raised series B2 round in March to push two highly stable ADC candidates into the clinic, and discover new payloads
BioCentury | Apr 12, 2024
Product Development
Cambrian explosion of ADCs at AACR24
Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
BioCentury | Mar 14, 2024
Finance
Venture Report: Tubulis’ big B round to advance ADCs, Relation adds to seed financing
Plus new rounds for Mission, Asgard and more
BioCentury | Jul 27, 2023
Politics, Policy & Law
July 27 Quick Takes: Rachel King out of the running for BIO CEO
Plus: Cross-border oncology play Adlai Nortye launches NASDAQ bid and updates for Lilly’s tirzepatide, Enhertu, Merck’s pneumococcal vaccine, UroGen, Mersana and Biohaven
BioCentury | Jun 15, 2023
Deals
June 15 Quick Takes: Astellas adds protein degraders in Cullgen deal
Plus: Zentalis, Editas are latest to tap investors for follow-on cash and updates from AbbVie, Mersana, Nordic Bioscience, Aldeyra, Theradaptive
BioCentury | Apr 21, 2023
Product Development
ADC advances at AACR: target diversity, optimizing internalization
BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
BioCentury | Feb 3, 2022
Deals
Mersana extends runway, gets $40M up front in three-ADC platform deal with J&J
Mersana’s early clinical, preclinical data inform J&J partnership around next-generation ADC platform
BioCentury | May 30, 2020
Finance
Ovarian cancer data help Mersana raise $152M to top off $9B month of follow-ons
BioCentury | Feb 16, 2019
Product Development
ADCs’ inflection point
How fit-for-purpose ADCs could open the modality’s floodgates
BioCentury | Sep 21, 2018
Clinical News
Mersana gets green light to resume ADC trial, but new dosing may slow progress
Items per page:
1 - 10 of 19